I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Hirabatake, Masaki
35
results:
Search for persons
X
Format
Online (35)
Mediatypes
Articles (Online) (20)
OpenAccess-fulltext (15)
Sorted by: Relevance
Sorted by: Year
?
1
Safety and blood levels of daratumumab after switching from..:
Yamaoka, Kenta
;
Irie, Kei
;
Hiramoto, Nobuhiro
...
Investigational New Drugs. 41 (2023) 5 - p. 761-767 , 2023
Link:
https://doi.org/10.1007/..
?
2
Pharmacokinetics of Temozolomide in a Patient With Glioblas..:
Tanaka, Fumiaki
;
Irie, Kei
;
Fukui, Nobuyuki
...
Therapeutic Drug Monitoring. 45 (2023) 6 - p. 823-826 , 2023
Link:
https://doi.org/10.1097/..
?
3
Pharmacist–Urologist Collaborative Management for Patients ..:
Hirabatake, Masaki
;
Ikesue, Hiroaki
;
Yoshino, Shintaro
...
Biological and Pharmaceutical Bulletin. 46 (2023) 8 - p. 1065-1071 , 2023
Link:
https://doi.org/10.1248/..
?
4
Impact of prior bevacizumab therapy on the incidence of ram..:
Dote, Satoshi
;
Shiwaku, Eiji
;
Kohno, Emiko
...
International Journal of Clinical Oncology. 28 (2023) 8 - p. 1054-1062 , 2023
Link:
https://doi.org/10.1007/..
?
5
Risk Factors of Proteinuria in Patients with Hepatocellular..:
Ikesue, Hiroaki
;
Yamamoto, Haruna
;
Hirabatake, Masaki
...
Biological and Pharmaceutical Bulletin. 45 (2022) 3 - p. 333-338 , 2022
Link:
https://doi.org/10.1248/..
?
6
Everolimus pharmacokinetics and exposure-response relations..:
Hirabatake, Masaki
;
Mizuno, Tomoyuki
;
Kato, Hironori
.
Frontiers in Pharmacology. 13 (2022) - p. , 2022
Link:
https://doi.org/10.3389/..
?
7
Pharmacist-Urologist Collaborative Management Improves Clin..:
Hirabatake, Masaki
;
Ikesue, Hiroaki
;
Iwama, Yuna
...
Frontiers in Pharmacology. 13 (2022) - p. , 2022
Link:
https://doi.org/10.3389/..
?
8
Population Pharmacokinetics of Nivolumab in Japanese Patien..:
Tohi, Makiko
;
Irie, Kei
;
Mizuno, Tomoyuki
...
Therapeutic Drug Monitoring. 45 (2022) 1 - p. 110-116 , 2022
Link:
https://doi.org/10.1097/..
?
9
Risk factors of proteinuria and potentially protective effe..:
Ikesue, Hiroaki
;
Yamaoka, Kenta
;
Matsumoto, Ayako
...
Cancer Chemotherapy and Pharmacology. 89 (2022) 6 - p. 833-838 , 2022
Link:
https://doi.org/10.1007/..
?
10
Evaluating the safety and efficiency of robotic dispensing ..:
Takase, Tomoki
;
Masumoto, Norio
;
Shibatani, Naoki
...
Journal of Pharmaceutical Health Care and Sciences. 8 (2022) 1 - p. , 2022
Link:
https://doi.org/10.1186/..
?
11
Associated characteristics and treatment outcomes of medica..:
Ikesue, Hiroaki
;
Mouri, Moe
;
Tomita, Hideaki
...
Supportive Care in Cancer. 29 (2021) 8 - p. 4763-4772 , 2021
Link:
https://doi.org/10.1007/..
?
12
Switching from zoledronic acid to denosumab increases the r..:
Ikesue, Hiroaki
;
Doi, Kohei
;
Morimoto, Mayu
...
Cancer Chemotherapy and Pharmacology. 87 (2021) 6 - p. 871-877 , 2021
Link:
https://doi.org/10.1007/..
?
13
Safety evaluation of enzalutamide dose-escalation strategy ..:
Miura, Rieko
;
Hirabatake, Masaki
;
Irie, Kei
...
Urologic Oncology: Seminars and Original Investigations. 39 (2021) 4 - p. 233.e15-233.e20 , 2021
Link:
https://doi.org/10.1016/..
?
14
Risk evaluation of denosumab and zoledronic acid for medica..:
Ikesue, Hiroaki
;
Doi, Kohei
;
Morimoto, Mayu
...
Supportive Care in Cancer. 30 (2021) 3 - p. 2341-2348 , 2021
Link:
https://doi.org/10.1007/..
?
15
A simplified method for therapeutic drug monitoring of mito..:
Ando, Motozumi
;
Hirabatake, Masaki
;
Yasui, Hisateru
...
Biomedical Chromatography. 34 (2020) 3 - p. , 2020
Link:
https://doi.org/10.1002/..
1-15